Tatsuro Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatsuro Suzuki has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Akio Niimi
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
3 shared publications - Hirotsugu Ohkubo
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
3 shared publications - Keima Ito
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
3 shared publications - Kensuke Fukumitsu
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
3 shared publications - Takehiro Uemura
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
3 shared publications - Tetsuya Oguri
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
3 shared publications
Latest Publications
- Open Access
Clinical Remission and Its Predictors After 12 Months of Biologic Therapy in Severe Asthma
Background/Objectives: The rates and predictors of clinical remission, a novel and practical therapeutic goal in severe asthma, have been inconsistently reported across studies. Data on clinical remission in Japanese patients remain limited. The aim of this study was to assess the rate of four-component clinical remission and its predictors in Japanese adult patients with severe asthma. Methods: This retrospective study enrolled adult patients with severe asthma who had initiated biologic therapy at least 12 months prior to inclusion at Nagoya City University Hospital. The primary endpoint was the achievement rate of four-component clinical remission, defined as (1) no maintenance oral corticosteroids (OCS); (2) no exacerbations for 12 months; (3) Asthma Control Test (ACT) score ≥ 20; and (4) forced expiratory volume in one second (FEV1) ≥ 80% of predicted. The secondary endpoint was to identify factors, including airway structural indices measured using chest computed tomography (CT), associated with clinical remission at 12 months. Results: Among 87 patients with severe asthma, 26 (30%) achieved four-component clinical remission after 12 months of biologic therapy. In univariate analysis, clinical remission was more frequently achieved in patients with chronic rhinosinusitis, higher FEV1 (% predicted), higher blood eosinophil counts, higher ACT scores, fewer exacerbations in the previous year, higher Lund–Mackay scores, and smaller airway wall thickness and luminal areas on CT (all p < 0.05). Multivariate analysis revealed that higher blood eosinophil counts and fewer exacerbations in the previous year were independently associated with clinical remission (both p < 0.05). Conclusions: After 12 months of biologic therapy, 30% of patients with severe asthma achieved four-component clinical remission. Higher blood eosinophil counts and fewer prior exacerbations were associated with higher remission rates.
Open AccessClinical Remission and Its Predictors After 12 Months of Biologic Therapy in Severe Asthma
Background/Objectives: The rates and predictors of clinical remission, a novel and practical therapeutic goal in severe asthma, have been inconsistently reported across studies. Data on clinical remission in Japanese patients remain limited. The aim of this study was to assess the rate of four-component clinical remission and its predictors in Japanese adult patients with severe asthma. Methods: This retrospective study enrolled adult patients with severe asthma who had initiated biologic therapy at least 12 months prior to inclusion at Nagoya City University Hospital. The primary endpoint was the achievement rate of four-component clinical remission, defined as (1) no maintenance oral corticosteroids (OCS); (2) no exacerbations for 12 months; (3) Asthma Control Test (ACT) score ≥ 20; and (4) forced expiratory volume in one second (FEV1) ≥ 80% of predicted. The secondary endpoint was to identify factors, including airway structural indices measured using chest computed tomography (CT), associated with clinical remission at 12 months. Results: Among 87 patients with severe asthma, 26 (30%) achieved four-component clinical remission after 12 months of biologic therapy. In univariate analysis, clinical remission was more frequently achieved in patients with chronic rhinosinusitis, higher FEV1 (% predicted), higher blood eosinophil counts, higher ACT scores, fewer exacerbations in the previous year, higher Lund–Mackay scores, and smaller airway wall thickness and luminal areas on CT (all p < 0.05). Multivariate analysis revealed that higher blood eosinophil counts and fewer exacerbations in the previous year were independently associated with clinical remission (both p < 0.05). Conclusions: After 12 months of biologic therapy, 30% of patients with severe asthma achieved four-component clinical remission. Higher blood eosinophil counts and fewer prior exacerbations were associated with higher remission rates.
- Open Access
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (3) , 362-378
Risk Factors for COVID-19 mRNA Vaccine-Associated Exacerbations in Patients With Obstructive Airway Diseases: REsearch for Asthma and COPD ExacerbaTION Caused by COVID-19 mRNA Vaccination (REACTION Study)
Suzuki T, et al. Allergy Asthma Immunol Res. 2026 May;18(3):362-378. https://doi.org/10.4168/aair.2026.18.3.362
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (3) , 362-378
Open AccessRisk Factors for COVID-19 mRNA Vaccine-Associated Exacerbations in Patients With Obstructive Airway Diseases: REsearch for Asthma and COPD ExacerbaTION Caused by COVID-19 mRNA Vaccination (REACTION Study)
Suzuki T, et al. Allergy Asthma Immunol Res. 2026 May;18(3):362-378. https://doi.org/10.4168/aair.2026.18.3.362
- Open Access
- 21 August 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (8)
COVID‐19 Vaccine‐Induced Severe Pneumonitis
Coronavirus disease 2019 (COVID‐19) has resulted in global morbidity, mortality, and societal disruption. COVID‐19 mRNA vaccination was mandatory in many countries for a period; however, severe adverse events have been observed in some individuals who received the vaccine. We report a case of COVID‐19 mRNA vaccine‐induced pneumonitis in a male patient whose cytokine levels were analysed prior to admission. His serum IgE level was high (347 U/mL), and several cytokines were elevated: TNFα was 1.2 pg/mL, IL‐6 was 156 pg/mL, and IL‐8 was 75.0 pg/mL. The patient developed severe respiratory failure requiring ventilatory support but recovered after steroid pulse therapy.
- 21 August 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (8)
Open AccessCOVID‐19 Vaccine‐Induced Severe Pneumonitis
Coronavirus disease 2019 (COVID‐19) has resulted in global morbidity, mortality, and societal disruption. COVID‐19 mRNA vaccination was mandatory in many countries for a period; however, severe adverse events have been observed in some individuals who received the vaccine. We report a case of COVID‐19 mRNA vaccine‐induced pneumonitis in a male patient whose cytokine levels were analysed prior to admission. His serum IgE level was high (347 U/mL), and several cytokines were elevated: TNFα was 1.2 pg/mL, IL‐6 was 156 pg/mL, and IL‐8 was 75.0 pg/mL. The patient developed severe respiratory failure requiring ventilatory support but recovered after steroid pulse therapy.
- Open Access
- 23 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3654
Dupilumab-Induced Remission in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: A 24-Month Study
Background: When considering the effects of dupilumab on severe chronic rhinosinusitis with nasal polyps (CRSwNPs), dupilumab is expected to achieve CRSwNPs remission. The aim of this study was to assess the rate of remission of CRSwNPs with comorbid asthma and its predictors on a 24-month course of dupilumab. Methods: Adult patients with severe CRSwNPs and comorbid asthma who had completed a 24-month course of dupilumab were included in this post hoc analysis. The primary outcome was the rate of CRSwNPs remission at 12 and 24 months of dupilumab. The secondary outcome was to identify factors associated with CRSwNPs remission at 12 and 24 months. Based on the European criteria and a previous definition, remission was defined as the absence of symptoms, improved quality of life, no need for surgery, no exacerbations, recovery of olfactory function, and inactive disease by nasal endoscopy for ≥12 months. A rigorous six-component remission, including olfactory testing, was initially used. Results: Of 16 patients, 4 (25%) and 5 (31%) achieved six-component remission of CRSwNPs at 12 and 24 months, respectively. Patients with shorter disease duration and better olfactory function at baseline achieved six-component remission of CRSwNPs more frequently than those without at 24 months (both p < 0.05). Conclusions: Remission of severe CRSwNPs with comorbid asthma is attainable with a 24-month course of dupilumab.
- 23 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3654
Open AccessDupilumab-Induced Remission in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: A 24-Month Study
Background: When considering the effects of dupilumab on severe chronic rhinosinusitis with nasal polyps (CRSwNPs), dupilumab is expected to achieve CRSwNPs remission. The aim of this study was to assess the rate of remission of CRSwNPs with comorbid asthma and its predictors on a 24-month course of dupilumab. Methods: Adult patients with severe CRSwNPs and comorbid asthma who had completed a 24-month course of dupilumab were included in this post hoc analysis. The primary outcome was the rate of CRSwNPs remission at 12 and 24 months of dupilumab. The secondary outcome was to identify factors associated with CRSwNPs remission at 12 and 24 months. Based on the European criteria and a previous definition, remission was defined as the absence of symptoms, improved quality of life, no need for surgery, no exacerbations, recovery of olfactory function, and inactive disease by nasal endoscopy for ≥12 months. A rigorous six-component remission, including olfactory testing, was initially used. Results: Of 16 patients, 4 (25%) and 5 (31%) achieved six-component remission of CRSwNPs at 12 and 24 months, respectively. Patients with shorter disease duration and better olfactory function at baseline achieved six-component remission of CRSwNPs more frequently than those without at 24 months (both p < 0.05). Conclusions: Remission of severe CRSwNPs with comorbid asthma is attainable with a 24-month course of dupilumab.